ANZCTR search results

This research aims to: (1) assess key implementation and sustainability indices of implementing an individualised physical activity program for children with chronic health conditions, (2) test preliminary effects of the individualised physical activity program on physical activity, health, and psychosocial outcomes, (3) determine the cost of delivering the program. Who is it for? You may be eligible for this study if you are a pediatric patient aged between 5 and 18 years with one of four chronic health conditions: type 1 diabetes, cancer, post-burn injuries, or cerebral palsy Study details The Move to Improve team will work with the child and family to develop an individualised physical activity program aligned with the participants’ goals. Participants will be encouraged to follow the program over the 8-week duration of the intervention. To support participation in the individualised program and address specific barriers to physical activity, the Move to Improve team will provide additional resources (e.g., information sheets) as required. Participants will receive weekly support as required and additional support from psychologist and dietitian if needed. The child's physical activity, quality of life, goal attainment, as well as other mental and physical changes, will be assessed at 6 and 12 months follow-up. It is hoped that findings from this study will support children with chronic health condition to be more physically active.

Access to gender affirming healthcare is challenging, especially if a transgender person lives in a rural area. Specialised gender clinics have waiting lists of >12 months. We aim to better support local GPs to deliver gender affirming care in local communities by evaluating a new co-designed shared care model plus tailored training program to start hormone therapy. We will evaluate patient quality of life, mental health and satisfaction with the program over 24 months as well as GP knowledge and confidence in transgender health.

This will be a pilot study to determine efficacy of combination clonidine, adrenaline, ropivacaine, lidocaine, dexamethasone combination in reducing pain, time to first opioid analgesia, and total opioid analgesia consumption postoperatively compared with combination lidocaine and ropivacaine. We hypothesise that the combination of the above medication will contribute to a longer lasting postoperative anaesthetic effect, such that patients will be more comfortable in the 24-48 hours post surgery, requiring less usage of opiate analgesia, and a quicker return to premorbid activity and function.

The proposed clinical study will investigate taking the investigational product under fasted or fed conditions. The investigational product is a potential treatment for Coronavirus disease 2019 (COVID-19) patients with mild to moderate disease. It is anticipated that the proposed combination therapy will minimize disease progression and thereby lessen the risk of hospitalization and death.

The proposed clinical study will investigate the safety of multiple doses of the IP over 10 days. This IP is being trialed as a potential treatment for Coronavirus disease 2019 (COVID-19) patients with mild to moderate disease. It is anticipated that the proposed combination therapy will minimize disease progression and thereby lessen the risk of hospitalization and death.

Rationale: Ureteric injury is a known risk associated with complex gynecological surgery given its variable anatomical course through the pelvis. Ureteric injury is associated with significant morbidity thus methods to reduce surgical complications are important. Objectives: The primary objective is to determine the feasibility of undertaking a four-arm randomized trial to determine the most effective method of introducing cystoscopic-guided intraurethral indocyanine green (ICG) solution for ureteric identification during laparoscopic gynecological surgery. The intended primary outcome of the final study will be surgeon opinion of ease of ureteric identification laparoscopically. Secondary objectives include assessing if improved ureteric visualisation reduces surgical time, reduces additional procedures such as repeat cystoscopy or additional radiological investigations such as CT-IVP and reduces ureteric injury.

Cardiac catheterisation is an invasive cardiac procedure performed for diagnostic (angiography) and/or therapeutic (percutaneous coronary intervention [PCI]) purposes. Transradial approach to catheterisation is common, Current protocols for TR Band® deflation have been noted by staff as challenging to meet, with a recent audit identifying inconsistencies in practice and delayed deflations. Prolonged inflation times can increase the risk of radial artery occlusion (RAO). Evidence suggests that accelerated deflation protocols are safe and feasible and may reduce patient discomfort and length of stay. Various protocols have been developed and tested however, few assessed bleeding outcomes, efficiency of deflation and patient comfort. This study aims to assess the feasibility of accelerated protocols for TR Band® deflation. Outcome measures will be bleeding complications, deflation time/steps and patient comfort.

The current study aims to evaluate the efficacy of Goodnight Poor Sleep, a brief sleep intervention, by examining the long term improvements in sleep and mental health. It is hypothesised that the intervention (GPS) group will have significantly better sleep and mental health at post-treatment compared to the active control group.

This trial will explore the role of exogenous cannabinoids in people with endometriosis and look at the effects of ingested cannabinoids on a number of outcomes including (a) pelvic pain symptoms, and (b) gastrointestinal inflammation. The project utilises a placebo controlled, double blind, three arm parallel group trial, including two active arms of medicinal cannabis products (1:1 THC/CBD, CBD isolate). Eligible participants (people with endometriosis) will be randomly allocated in a 1:1:1 ratio to THC:CBD, CBD-isolate, or placebo oil products. The intervention phase is 3 months/menstrual cycles and follow-up phase is 2 months/menstrual cycles. The primary outcome is mean severity of endometriosis symptoms (pelvic pain, fatigue, nausea and gastrointestinal symptoms) and explore any in association between changes in symptoms and gut microbiota, endocannabinoids and vaginal microflora. Adverse event data will be collected during the trial and follow-up phase.

This study is evaluating the adaptations required to implement on-site pharmacists into residential aged care facilities (RACHs) in urban, regional, rural and remote areas. The study is seeking to understand what are the barriers and enablers that assist rural, regional and remote aged care homes to employ a pharmacist as part of the aged care home operations. The study will also assess the impact that having an on-site pharmacist with an aged care home has on aged care quality indicators.